These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8530590)

  • 21. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome.
    Genazzani AD; Santagni S; Ricchieri F; Campedelli A; Rattighieri E; Chierchia E; Marini G; Despini G; Prati A; Simoncini T
    J Obstet Gynaecol Res; 2014 May; 40(5):1353-60. PubMed ID: 24606639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential androgen response to adrenocorticotrophin hormone stimulation and effect of opioid antagonist on insulin secretion in polycystic ovarian syndrome.
    Lanzone A; Fulghesu AM; Guido M; Ciampelli M; Caruso A; Mancuso S
    Hum Reprod; 1994 Dec; 9(12):2242-6. PubMed ID: 7714138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia.
    Lanzone A; Villa P; Fulghesu AM; Pavone V; Caruso A; Mancuso S
    Hum Reprod; 1995 Jul; 10(7):1653-7. PubMed ID: 8582956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of the endogenous opioid system in the pathogenesis of polycystic ovary syndrome: the altered neuroendocrine regulation of GnRH-LH is corrected after clomiphene therapy].
    Barletta C; Vagiri D; Scavo D
    Minerva Endocrinol; 1992; 17(3):107-19. PubMed ID: 1298870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome.
    Billa E; Kapolla N; Nicopoulou SC; Koukkou E; Venaki E; Milingos S; Antsaklis A; Adamopoulos DA
    Gynecol Endocrinol; 2009 Jul; 25(7):427-34. PubMed ID: 19533481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist.
    Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S
    Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LH pulsatility and response to a single s.c. injection of buserelin in polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Balint-Peric L
    Gynecol Endocrinol; 1990 Mar; 4(1):1-13. PubMed ID: 2110712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
    Wang A; Li M; Lu C
    Zhonghua Fu Chan Ke Za Zhi; 1998 Dec; 33(12):731-4. PubMed ID: 10806662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine control in polycystic ovary-like syndrome.
    Schoemaker J
    Gynecol Endocrinol; 1991 Dec; 5(4):277-88. PubMed ID: 1796749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
    Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
    Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia.
    Ciotta L; De Leo V ; Farina M; Pafumi C; La Marca A ; Cianci A
    Gynecol Obstet Invest; 2001; 51(1):44-50. PubMed ID: 11150875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome.
    Lanzone A; Apa R; Fulghesu AM; Cutillo G; Caruso A; Mancuso S
    Fertil Steril; 1993 Apr; 59(4):734-7. PubMed ID: 8458488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of naltrexone in postmenopausal women with exaggerated insulin secretion: a pilot study.
    Cucinelli F; Soranna L; Perri C; Barini A; Cento RM; Mancuso S; Lanzone A
    Fertil Steril; 2004 Apr; 81(4):1047-54. PubMed ID: 15066462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of opioid blockade on insulin metabolism in polycystic ovarian disease.
    Fulghesu AM; Ciampelli M; Fortini A; Cucinelli F; Guido M; Caruso A; Lanzone A; Mancuso S
    Hum Reprod; 1995 Sep; 10(9):2253-7. PubMed ID: 8530646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperinsulinemia in the polycystic ovary syndrome: a clinical, endocrine and echographic study in 240 patients.
    Falsetti L; Eleftheriou G
    Gynecol Endocrinol; 1996 Oct; 10(5):319-26. PubMed ID: 8915661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of opioid antagonists in the treatment of women with glucoregulation abnormalities.
    Guido M; Romualdi D; Lanzone A
    Curr Pharm Des; 2006; 12(8):1001-12. PubMed ID: 16533167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.